drugset / Trial / NCT01325233

The Pilot Clinical Study of PG2 Injection on Hemorrhagic Stroke

NCT01325233 ↗

Phase 0 Completed 61 enrolled PhytoHealth Corporation
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Astragalus membranaceus (AM) is used to treat stroke for a long time, and a number of studies have shown that AM can reduce cerebral infarction area and has anti-oxidation activity. PG2, a sterile powder of polysaccharides isolated from the root of astragulus (Huang-Chi) for intravenous injection, has been approved as a botanical drug by TFDA. Hemorrhagic stroke will induce secondary peri-blood clot edema and that may increase intracranial pressure to exacerbate clinical symptom. Therefore, the purpose of the present study was to investigate the efficacy of PG2 on hemorrhagic stroke.

Timeline

Start
2011-03
Primary completion
2013-09
Completion
2013-09

Drugs

EvaluationDrugModalityDoseRoute
Subject PG2 Unknown 500 mg Intravenous

Indications